Published in J Proteome Res on February 01, 2007
Gut microbiome-host interactions in health and disease. Genome Med (2011) 2.48
Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. Mol Syst Biol (2008) 2.43
Metabolomics reveals metabolic biomarkers of Crohn's disease. PLoS One (2009) 2.35
Metabolic phenotyping in clinical and surgical environments. Nature (2012) 2.09
Role of the gut microbiota in defining human health. Expert Rev Anti Infect Ther (2010) 1.73
Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Therap Adv Gastroenterol (2013) 1.56
Investigating the biological and clinical significance of human dysbioses. Trends Microbiol (2011) 1.48
A metabolomic view of how the human gut microbiota impacts the host metabolome using humanized and gnotobiotic mice. ISME J (2013) 1.42
Inflammatory bowel disease as a model for translating the microbiome. Immunity (2014) 1.39
Retracted Dextran sulfate sodium inhibits alanine synthesis in Caco-2 cells. Int J Mol Sci (2011) 1.39
Host genetic variation impacts microbiome composition across human body sites. Genome Biol (2015) 1.32
Metabonomic fingerprints of fasting plasma and spot urine reveal human pre-diabetic metabolic traits. Metabolomics (2010) 1.24
Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol (2011) 1.23
Quantitative metabolomic profiling of serum, plasma, and urine by (1)H NMR spectroscopy discriminates between patients with inflammatory bowel disease and healthy individuals. J Proteome Res (2012) 1.21
Standard operating procedures for pre-analytical handling of blood and urine for metabolomic studies and biobanks. J Biomol NMR (2011) 1.15
Impact of a synbiotic food on the gut microbial ecology and metabolic profiles. BMC Microbiol (2010) 1.10
The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med (2016) 1.08
Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models. Mutat Res (2010) 1.06
Variable alterations of the microbiota, without metabolic or immunological change, following faecal microbiota transplantation in patients with chronic pouchitis. Sci Rep (2015) 1.03
Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis. Arthritis Rheum (2013) 1.01
Application of a novel tool for diagnosing bile acid diarrhoea. Sensors (Basel) (2013) 1.00
Alteration of the fecal microbiota and serum metabolite profiles in dogs with idiopathic inflammatory bowel disease. Gut Microbes (2015) 0.98
The impact of inflammation on metabolomic profiles in patients with arthritis. Arthritis Rheum (2013) 0.97
Gallic acid ameliorated impaired glucose and lipid homeostasis in high fat diet-induced NAFLD mice. PLoS One (2014) 0.97
Clinical metabolomics paves the way towards future healthcare strategies. Br J Clin Pharmacol (2013) 0.95
Butyrate attenuates lipopolysaccharide-induced inflammation in intestinal cells and Crohn's mucosa through modulation of antioxidant defense machinery. PLoS One (2012) 0.95
Potential probiotic Kluyveromyces marxianus B0399 modulates the immune response in Caco-2 cells and peripheral blood mononuclear cells and impacts the human gut microbiota in an in vitro colonic model system. Appl Environ Microbiol (2011) 0.93
Reduced diversity and imbalance of fecal microbiota in patients with ulcerative colitis. Dig Dis Sci (2012) 0.92
Metabolomics--a novel window into inflammatory disease. Swiss Med Wkly (2013) 0.91
Insulin sensitivity is reflected by characteristic metabolic fingerprints--a Fourier transform mass spectrometric non-targeted metabolomics approach. PLoS One (2010) 0.90
Application of metagenomics in the human gut microbiome. World J Gastroenterol (2015) 0.90
A study in balance: how microbiomes are changing the shape of environmental health. Environ Health Perspect (2011) 0.88
Application of phylogenetic microarrays to interrogation of human microbiota. FEMS Microbiol Ecol (2011) 0.88
Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut. Front Microbiol (2016) 0.87
Metabolomic analysis of human disease and its application to the eye. J Ocul Biol Dis Infor (2009) 0.87
Metabonomics of human fecal extracts characterize ulcerative colitis, Crohn's disease and healthy individuals. Metabolomics (2014) 0.87
Metabonomic analysis reveals efficient ameliorating effects of acupoint stimulations on the menopause-caused alterations in mammalian metabolism. Sci Rep (2014) 0.87
Metabolomic applications to decipher gut microbial metabolic influence in health and disease. Front Physiol (2012) 0.87
Metabolomics as a diagnostic tool in gastroenterology. World J Gastrointest Pharmacol Ther (2013) 0.87
A Disease-Associated Microbial and Metabolomics State in Relatives of Pediatric Inflammatory Bowel Disease Patients. Cell Mol Gastroenterol Hepatol (2016) 0.87
Genetic basis of metabolome variation in yeast. PLoS Genet (2014) 0.87
Elevated pro-inflammatory and lipotoxic mucosal lipids characterise irritable bowel syndrome. World J Gastroenterol (2009) 0.86
The human microbiome is a source of therapeutic drug targets. Curr Opin Chem Biol (2013) 0.86
Identification of urinary biomarkers of colon inflammation in IL10-/- mice using Short-Column LCMS metabolomics. J Biomed Biotechnol (2010) 0.86
The role of the immune system in regulating the microbiota. Gut Microbes (2010) 0.85
Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases. World J Gastroenterol (2014) 0.85
Phylogenetic and Metabolic Tracking of Gut Microbiota during Perinatal Development. PLoS One (2015) 0.84
Gut Microbiota Profiling: Metabolomics Based Approach to Unravel Compounds Affecting Human Health. Front Microbiol (2016) 0.83
Dietary requirement for serum-derived bovine immunoglobulins in the clinical management of patients with enteropathy. Dig Dis Sci (2014) 0.82
Metabolomics: is it useful for inflammatory bowel diseases? Curr Opin Gastroenterol (2013) 0.82
Next generation sequencing and a new era of medicine. Gut (2012) 0.82
MRI for Crohn's Disease: Present and Future. Biomed Res Int (2015) 0.81
Integration of datasets from different analytical techniques to assess the impact of nutrition on human metabolome. Front Cell Infect Microbiol (2012) 0.81
Mechanisms of Microbe-Host Interaction in Crohn's Disease: Dysbiosis vs. Pathobiont Selection. Front Immunol (2015) 0.80
Correlations of Fecal Metabonomic and Microbiomic Changes Induced by High-fat Diet in the Pre-Obesity State. Sci Rep (2016) 0.80
NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget (2016) 0.80
Metabolic profiling of the impact of oligofructose-enriched inulin in Crohn's disease patients: a double-blinded randomized controlled trial. Clin Transl Gastroenterol (2013) 0.80
Dysbiosis and the immune system. Nat Rev Immunol (2017) 0.79
1H NMR-based metabolomics investigation of copper-laden rat: a model of Wilson's disease. PLoS One (2015) 0.79
Microbiome, Metabolome and Inflammatory Bowel Disease. Microorganisms (2016) 0.78
Metabolomic profiles are gender, disease and time specific in the interleukin-10 gene-deficient mouse model of inflammatory bowel disease. PLoS One (2013) 0.78
Activation of the umami taste receptor (T1R1/T1R3) initiates the peristaltic reflex and pellet propulsion in the distal colon. Am J Physiol Gastrointest Liver Physiol (2014) 0.78
Stool phospholipid signature is altered by diet and tumors. PLoS One (2014) 0.78
Toward the comprehensive understanding of the gut ecosystem via metabolomics-based integrated omics approach. Semin Immunopathol (2014) 0.78
Caring about trees in the forest: incorporating frailty in risk analysis for personalized medicine. Per Med (2011) 0.77
The role of the gut microbiome in the pathogenesis and treatment of obesity. Glob Adv Health Med (2014) 0.77
Metabolite analysis distinguishes between mice with epidermolysis bullosa acquisita and healthy mice. Orphanet J Rare Dis (2013) 0.77
Fecal metabolome of the Hadza hunter-gatherers: a host-microbiome integrative view. Sci Rep (2016) 0.76
Gut microbiome in chronic kidney disease: challenges and opportunities. Transl Res (2016) 0.76
The kiwi fruit peptide kissper displays anti-inflammatory and anti-oxidant effects in in-vitro and ex-vivo human intestinal models. Clin Exp Immunol (2014) 0.76
Metabonomics exposes metabolic biomarkers of Crohn's disease by (1)HNMR. Gastroenterol Hepatol Bed Bench (2013) 0.76
Metabolomics: A Tool Ahead for Understanding Molecular Mechanisms of Drugs and Diseases. Indian J Clin Biochem (2014) 0.76
Update on current applications of proteomic in the study of inflammatory bowel disease. Ann Gastroenterol (2012) 0.75
(1)H-NMR analysis of feces: new possibilities in the helminthes infections research. BMC Infect Dis (2017) 0.75
Biomarkers for colitis-associated colorectal cancer. World J Gastroenterol (2016) 0.75
Dietary Protein and Amino Acid Supplementation in Inflammatory Bowel Disease Course: What Impact on the Colonic Mucosa? Nutrients (2017) 0.75
Butyrate and bioactive proteolytic form of Wnt-5a regulate colonic epithelial proliferation and spatial development. Sci Rep (2016) 0.75
Comparison of Collection Methods for Fecal Samples for Discovery Metabolomics in Epidemiologic Studies. Cancer Epidemiol Biomarkers Prev (2016) 0.75
Current tecniques and new perpectives research of magnetic resonance enterography in pediatric Crohn's disease. World J Radiol (2016) 0.75
Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease. World J Gastrointest Pharmacol Ther (2016) 0.75
Fecal metabolomics in pediatric spondyloarthritis implicate decreased metabolic diversity and altered tryptophan metabolism as pathogenic factors. Genes Immun (2016) 0.75
New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes. Inflamm Bowel Dis (2016) 0.75
Roles of Dietary Amino Acids and Their Metabolites in Pathogenesis of Inflammatory Bowel Disease. Mediators Inflamm (2017) 0.75
Intestinal metabolites are profoundly altered in the context of HLA-B27 expression and functionally modulate disease in a rat model of spondyloarthropathy. Arthritis Rheumatol (2017) 0.75
Host-gut microbiota metabolic interactions. Science (2012) 7.73
The gut flora as a forgotten organ. EMBO Rep (2006) 7.42
Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science (2013) 6.98
Gut microbiota composition correlates with diet and health in the elderly. Nature (2012) 6.94
Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci U S A (2008) 6.42
Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov (2002) 5.96
Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc (2007) 5.92
Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology (2005) 5.75
Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol (2005) 5.35
Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A (2006) 5.19
Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A (2010) 5.02
TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev (2008) 4.85
Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov (2003) 4.46
Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol (2010) 4.45
Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal Chem (2005) 4.14
Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc (2011) 4.13
Chemometrics in metabonomics. J Proteome Res (2007) 4.02
Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med (2002) 3.91
A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model. Mol Syst Biol (2007) 3.68
Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut (2011) 3.42
Large-scale human metabolomics studies: a strategy for data (pre-) processing and validation. Anal Chem (2006) 3.24
Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol (2006) 3.24
Culture-independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn's disease. J Clin Microbiol (2006) 2.93
Summary recommendations for standardization and reporting of metabolic analyses. Nat Biotechnol (2005) 2.90
Multiple parasite infections and their relationship to self-reported morbidity in a community of rural Côte d'Ivoire. Int J Epidemiol (2004) 2.84
Metabolic phenotyping in health and disease. Cell (2008) 2.80
Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci U S A (2010) 2.52
Multireplicon genome architecture of Lactobacillus salivarius. Proc Natl Acad Sci U S A (2006) 2.43
Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. Mol Syst Biol (2008) 2.43
Exploring the diversity of the bifidobacterial population in the human intestinal tract. Appl Environ Microbiol (2009) 2.34
Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology (2006) 2.28
Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity. Gut (2012) 2.24
Functional genome analysis of Bifidobacterium breve UCC2003 reveals type IVb tight adherence (Tad) pili as an essential and conserved host-colonization factor. Proc Natl Acad Sci U S A (2011) 2.22
Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog (2008) 2.21
The role of substance P in inflammatory disease. J Cell Physiol (2004) 2.19
Global metabolic profiling procedures for urine using UPLC-MS. Nat Protoc (2010) 2.18
Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes. Mol Syst Biol (2008) 2.17
UPLC/MS(E); a new approach for generating molecular fragment information for biomarker structure elucidation. Rapid Commun Mass Spectrom (2006) 2.17
Transcriptome shock after interspecific hybridization in senecio is ameliorated by genome duplication. Curr Biol (2006) 2.16
NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed (2005) 2.15
Site and strain-specific variation in gut microbiota profiles and metabolism in experimental mice. PLoS One (2010) 2.14
Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci U S A (2010) 2.11
Metabonomic investigations in mice infected with Schistosoma mansoni: an approach for biomarker identification. Proc Natl Acad Sci U S A (2004) 2.11
Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. Proc Natl Acad Sci U S A (2012) 2.09
Metabolic phenotyping in clinical and surgical environments. Nature (2012) 2.09
Celiac disease and irritable bowel-type symptoms. Am J Gastroenterol (2002) 2.07
Development of a robust and repeatable UPLC-MS method for the long-term metabolomic study of human serum. Anal Chem (2009) 2.06
Colonization-induced host-gut microbial metabolic interaction. MBio (2011) 2.04
The challenges of modeling mammalian biocomplexity. Nat Biotechnol (2004) 2.03
Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol (2010) 2.02
Optimized preprocessing of ultra-performance liquid chromatography/mass spectrometry urinary metabolic profiles for improved information recovery. Anal Chem (2011) 2.02
Analytical strategies in metabonomics. J Proteome Res (2007) 2.00
Enterococcus faecalis metalloprotease compromises epithelial barrier and contributes to intestinal inflammation. Gastroenterology (2011) 1.96
Susceptibility of human metabolic phenotypes to dietary modulation. J Proteome Res (2006) 1.96
Metabonomics in pharmaceutical R&D. FEBS J (2007) 1.93
Using chemometrics for navigating in the large data sets of genomics, proteomics, and metabonomics (gpm). Anal Bioanal Chem (2004) 1.88
The human gut microbiome: implications for future health care. Curr Gastroenterol Rep (2008) 1.84
Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. J Proteome Res (2010) 1.84
A genome-wide metabolic QTL analysis in Europeans implicates two loci shaped by recent positive selection. PLoS Genet (2011) 1.83
Scaling and normalization effects in NMR spectroscopic metabonomic data sets. Anal Chem (2006) 1.81
MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. Hepatology (2009) 1.79
Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers (2004) 1.79
Global metabolic responses of NMRI mice to an experimental Plasmodium berghei infection. J Proteome Res (2008) 1.78
NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem Res Toxicol (2008) 1.77
Assessment of analytical reproducibility of 1H NMR spectroscopy based metabonomics for large-scale epidemiological research: the INTERMAP Study. Anal Chem (2006) 1.76
High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat Protoc (2010) 1.76
Within-day reproducibility of an HPLC-MS-based method for metabonomic analysis: application to human urine. J Proteome Res (2007) 1.74
Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius. Immunology (2006) 1.73
The mycobacteria story in Crohn's disease. Am J Gastroenterol (2005) 1.71
Metabonomic and microbiological analysis of the dynamic effect of vancomycin-induced gut microbiota modification in the mouse. J Proteome Res (2008) 1.67
Application of chemometrics to 1H NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. Analyst (2003) 1.65
Precision of GE Lunar iDXA for the measurement of total and regional body composition in nonobese adults. J Clin Densitom (2012) 1.63
Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm Bowel Dis (2013) 1.63
Statistical heterospectroscopy, an approach to the integrated analysis of NMR and UPLC-MS data sets: application in metabonomic toxicology studies. Anal Chem (2006) 1.61
Plant responses to cold: Transcriptome analysis of wheat. Plant Biotechnol J (2010) 1.61
Human metabolic profiles are stably controlled by genetic and environmental variation. Mol Syst Biol (2011) 1.60
Recursive segment-wise peak alignment of biological (1)h NMR spectra for improved metabolic biomarker recovery. Anal Chem (2009) 1.59
Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio (2012) 1.59
Systems biology tools for toxicology. Arch Toxicol (2012) 1.58